Eli Lilly & Co. paired its third quarter earnings call with news of a big leadership change. Longtime diabetes executive Enrique Conterno will be retiring at year’s end, to be succeeded by a fellow Lilly veteran, Mike Mason.
Serving most recently as president of Lilly Diabetes, Conterno has had a pivotal role shaping the company’s diabetes business, a...








